5 Key Takeaways
-
1
Subretinal hyperreflective material (SHRM) is a critical predictor of visual outcomes in patients.
-
2
The TENAYA and LUCERNE studies evaluated the effects of faricimab on SHRM compared to aflibercept.
-
3
Faricimab demonstrated a greater reduction in both area and volume of SHRM during the loading phase.
-
4
The presence of SHRM at 12 weeks is a significant predictor of long-term vision outcomes.
-
5
Eliminating SHRM early is essential for achieving optimal vision outcomes in patients.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
